Apellis Pharmaceuticals Develops $33M Series C Round
December 03, 2014
Apellis Pharmaceuticals has raised $33 million in Series C funding at a valuation of $75 million. Morningside Ventures and AJU IB Investment co-led the round, the proceeds from which will be used to fund three new complement immunotherapy programs entering clinical proof-of-concept stage. Apellis's immunotherapies are designed to correct auto-immune conditions.